These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29894000)

  • 1. Impact of menopause on outcomes in prolactinomas after dopamine agonist treatment withdrawal.
    Santharam S; Fountas A; Tampourlou M; Arlt W; Ayuk J; Gittoes N; Toogood A; Karavitaki N
    Clin Endocrinol (Oxf); 2018 Sep; 89(3):346-353. PubMed ID: 29894000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Withdrawal of dopamine agonist therapy in prolactinomas: In which patients and when?
    Dogansen SC; Selcukbiricik OS; Tanrikulu S; Yarman S
    Pituitary; 2016 Jun; 19(3):303-10. PubMed ID: 26830552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of quinagolide and cabergoline, two selective dopamine receptor type 2 agonists, in the treatment of prolactinomas.
    Di Sarno A; Landi ML; Marzullo P; Di Somma C; Pivonello R; Cerbone G; Lombardi G; Colao A
    Clin Endocrinol (Oxf); 2000 Jul; 53(1):53-60. PubMed ID: 10931080
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prolactinoma management: predictors of remission and recurrence after dopamine agonists withdrawal.
    Teixeira M; Souteiro P; Carvalho D
    Pituitary; 2017 Aug; 20(4):464-470. PubMed ID: 28523537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cabergoline Withdrawal Before and After Menopause: Outcomes in Microprolactinomas.
    Indirli R; Ferrante E; Sala E; Giavoli C; Mantovani G; Arosio M
    Horm Cancer; 2019 Jun; 10(2-3):120-127. PubMed ID: 31001736
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Best candidates for dopamine agonist withdrawal in patients with prolactinomas.
    Ji MJ; Kim JH; Lee JH; Lee JH; Kim YH; Paek SH; Shin CS; Kim SY
    Pituitary; 2017 Oct; 20(5):578-584. PubMed ID: 28710724
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long term follow-up of patients with prolactinomas and outcome of dopamine agonist withdrawal: a single center experience.
    Anagnostis P; Adamidou F; Polyzos SA; Efstathiadou Z; Karathanassi E; Kita M
    Pituitary; 2012 Mar; 15(1):25-9. PubMed ID: 21409614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Women with prolactinomas presented at the postmenopausal period.
    Shimon I; Bronstein MD; Shapiro J; Tsvetov G; Benbassat C; Barkan A
    Endocrine; 2014 Dec; 47(3):889-94. PubMed ID: 24711223
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolactinomas: evolution after menopause.
    Mallea-Gil MS; Manavela M; Alfieri A; Ballarino MC; Chervin A; Danilowicz K; Diez S; Fainstein Day P; García-Basavilbaso N; Glerean M; Guitelman M; Katz D; Loto MG; Martinez M; Miragaya K; Moncet D; Rogozinski AS; Servidio M; Stalldecker G; Vitale M; Boero L
    Arch Endocrinol Metab; 2016 Feb; 60(1):42-6. PubMed ID: 26909481
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Radiographic and Hormonal Regression in Prolactinomas: An Analysis of Treatment Failure.
    Akinduro OO; Lu VM; Izzo A; De Biase G; Vilanilam G; Van Gompel JJ; Bernet V; Donaldson A; Olomu O; Meyer FB; Quinones-Hinojosa A; Chaichana KL
    World Neurosurg; 2019 Sep; 129():e686-e694. PubMed ID: 31181361
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide.
    Colao A; Ferone D; Lastoria S; Cerbone G; Di Sarno A; Di Somma C; Lucci R; Lombardi G
    Clin Endocrinol (Oxf); 2000 Apr; 52(4):437-45. PubMed ID: 10762286
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High biochemical recurrence rate after withdrawal of cabergoline in prolactinomas: is it necessary to restart treatment?
    Espinosa-Cárdenas E; Sánchez-García M; Ramírez-Rentería C; Mendoza-Zubieta V; Sosa-Eroza E; Mercado M
    Endocrine; 2020 Oct; 70(1):143-149. PubMed ID: 32548734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization.
    Colao A; Di Somma C; Loche S; Di Sarno A; Klain M; Pivonello R; Pietrosante M; Salvatore M; Lombardi G
    Clin Endocrinol (Oxf); 2000 Mar; 52(3):319-27. PubMed ID: 10718830
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolactinoma in postmenopausal women: a systematic review.
    Carneiro MS; de Mira TAA; Yela DA; Benetti-Pinto CL
    Menopause; 2024 Feb; 31(2):160-167. PubMed ID: 38194617
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recurrence of hyperprolactinaemia following discontinuation of dopamine agonist therapy in patients with prolactinoma occurs commonly especially in macroprolactinoma.
    Barber TM; Kenkre J; Garnett C; Scott RV; Byrne JV; Wass JA
    Clin Endocrinol (Oxf); 2011 Dec; 75(6):819-24. PubMed ID: 21645021
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 10-year follow-up study comparing primary medical vs. surgical therapy in women with prolactinomas.
    Andereggen L; Frey J; Andres RH; El-Koussy M; Beck J; Seiler RW; Christ E
    Endocrine; 2017 Jan; 55(1):223-230. PubMed ID: 27688009
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors determining the remission of microprolactinomas after dopamine agonist withdrawal.
    Huda MS; Athauda NB; Teh MM; Carroll PV; Powrie JK
    Clin Endocrinol (Oxf); 2010 Apr; 72(4):507-11. PubMed ID: 19549247
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resistant prolactinomas: a case series of 26 patients.
    Eshkoli T; Fraenkel M; Zaid D; Cohen D; Yoel U; Tsvetov G; Gorshtein A; Goldbart A; Greenman Y; Shimon I
    Endocrine; 2022 Aug; 77(2):349-356. PubMed ID: 35604631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. THE EFFECT OF RALOXIFENE ON SERUM PROLACTIN LEVEL IN PATIENTS WITH PROLACTINOMA.
    Choudhary C; Hamrahian AH; Bena JF; Recinos P; Kennedy L; Dobri G
    Endocr Pract; 2019 Jul; 25(7):684-688. PubMed ID: 30865525
    [No Abstract]   [Full Text] [Related]  

  • 20. Diagnosis and drug therapy of prolactinoma.
    Ciccarelli E; Camanni F
    Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.